Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Andrews, K Abigail ^a   Modat, Marc ^a   Macdonald, Kate E ^a   Yeatman, Tom ^a   Cardoso, M Jorge ^a   Leung, Kelvin K ^a   Barnes, Josephine ^a   Villemagne, Victor L ^b   Rowe, Christopher C ^b   Fox, Nick C ^a   Ourselin, Sebastien ^a   Schott, Jonathan M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN ATROPHY; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREVENTION STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOSIS; APOLIPOPROTEINS E; ATROPHY; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; ORGAN SIZE; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84875031646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058816     Document Type: Article

References (50)

1. Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, et al. (2011) Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26Suppl 3: 321-329 doi:10.3233/JAD-2011-0059.
2. Herholz K, Ebmeier K, (2011) Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 10: 667-670 doi:10.1016/S1474-4422(11)70123-5.
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319 doi:10.1002/ana.20009.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393 doi:10.1001/jama.2009.1064.
5. Fox NC, Schott JM, (2004) Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 363: 392-394 doi:10.1016/S0140-6736(04)15441-X.
6. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128 doi:10.1016/S1474-4422(09)70299-6.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. Vol. 7: 280-292 doi:10.1016/j.jalz.2011.03.003.
8. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, et al. (2011) Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3: 1 doi:10.1186/alzrt59.
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413 doi:10.1002/ana.21610.
10. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, et al. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31: 1275-1283 doi:10.1016/j.neurobiolaging.2010.04.007.
11. Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, et al. (2010) Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74: 121-127 doi:10.1212/WNL.0b013e3181c918b5.
12. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, et al. (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130: 2837-2844 doi:10.1093/brain/awm238.
13. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, et al. (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680 doi:10.1093/brain/awm336.
14. Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, et al. (2012) β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 78: 387-395 doi:10.1212/WNL.0b013e318245d295.
15. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65(11): 1509-17 doi: 10.1001/archneur.65.11.1509.16.
16. Morris JC, Roe CM, Grant EA, Head D, Storandt M, et al. (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66: 1469-1475 doi:10.1001/archneurol.2009.269.
17. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, et al. (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69: 181-192 doi:10.1002/ana.22248.
18. Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, et al. (2012) Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78: 1576-1582 doi:10.1212/WNL.0b013e3182563bbe.
19. Strobel G (2011) Anti-Amyloid Treatment in Asymptomatic AD Trial Alzheimer Research Forum. Available at: http://www.alzforum.org/new/detail.asp?id=3014. Accessed 1 June 2012.
20. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, et al. (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21: 672-687 doi:10.1017/S1041610209009405.
21. Boyes RG, Gunter JL, Frost C, Janke AL, Yeatman T, et al. (2008) Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. Neuroimage 39: 1752-1762 doi:10.1016/j.neuroimage.2007.10.026.
22. Lewis EB, Fox NC, (2004) Correction of differential intensity inhomogeneity in longitudinal MR images. Neuroimage 23: 75-83 doi:10.1016/j.neuroimage.2004.04.030.
23. Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, et al. (2011) Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage 55: 1091-1108 doi:10.1016/j.neuroimage.2010.12.067.
24. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, et al. (2010) Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 51: 1345-1359 doi:10.1016/j.neuroimage.2010.03.018.
25. Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, et al. (2010) Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. Eur Radiol 20: 674-682 doi:10.1007/s00330-009-1581-5.
26. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, et al. (2010) Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging 31: 1452-62, 1462.e1-2. doi:10.1016/j.neurobiolaging.2010.04.011.
27. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, et al. (2010) Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage 50: 516-523 doi:10.1016/j.neuroimage.2009.12.059.
28. Athinoula A. Martinos Center at the Massachusetts General Hospital, Harvard Medical School. FreeSurfer. Available to download at: http://www.surfer.nmr.mgh.harvard.edu/.
29. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, et al. (2004) A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage 23: 724-738 doi:10.1016/j.neuroimage.2004.06.018.
30. Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, et al. (2011) LoAd: a locally adaptive cortical segmentation algorithm. Neuroimage 56: 1386-1397 doi:10.1016/j.neuroimage.2011.02.013.
31. Cardoso MJ, Leung KK, Modat M, Keihaninejad S, Cash D, et al. (2013) STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcellation. Medical Image Analysis (in press).
32. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, et al. (2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19: 224-247 doi:10.1002/hbm.10123.
33. Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, et al. (2010) Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed 98: 278-284 doi:10.1016/j.cmpb.2009.09.002.
34. Ourselin S, Roche A, Subsol G, Pennec X, Ayache N, (2001) Reconstructing a 3D structure from serial histological sections. Image and Vision Computing. Vol. 19: 25-31.
35. WARD J (1963) Hierarchical Grouping to Optimize an Objective Function. J Am Stat Assoc 58: 236
36. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al. (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78: 477-484 doi:10.1212/WNL.0b013e318246d67a.
37. Schott JM, Bartlett JW, Fox NC, Barnes J, Alzheimer's Disease Neuroimaging Initiative Investigators, (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 68: 825-834 doi:10.1002/ana.22315.
38. Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW, et al. (2011) Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 134: 1077-1088 doi:10.1093/brain/awr044.
39. Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, et al. (2010) Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133: 3349-3358 doi:10.1093/brain/awq187.
40. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, et al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67: 949-956 doi:10.1001/archneurol.2010.179.
41. Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519 doi:10.1002/ana.20730.
42. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, et al. (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133: 3336-3348 doi:10.1093/brain/awq277.
43. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, et al. (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 (Pt 6): 2001-2007.
44. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131 doi:10.1002/ana.21843.
45. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070 doi:10.1212/WNL.0b013e3181c67808.
46. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, et al. (2006) Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J Neurol 253: 1147-1153 doi:10.1007/s00415-006-0173-4.
47. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, et al. (2011) Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 95: 594-600 doi:10.1016/j.pneurobio.2011.08.014.
48. Barnes J, Foster J, Boyes RG, Pepple T, Moore EK, et al. (2008) A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. NeuroImage 40: 1655-1671 doi:10.1016/j.neuroimage.2008.01.012.
49. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572 doi:10.1212/01.WNL.0000159743.08996.99.
50. Fox NC (2012) Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoproteinE e4 carriers (Study 302) and non-carriers (Study 301): CSF and Volumetric MRI Biomarkers. Clinical Trials in Alzheimer's Disease. Available at: http://www.ctad.fr/07-download/Congres2012/PressRelease/Final-Fox-CTAD-Presentation-10-29-12.pdf. Accessed: 27 Nov 2012.